Pancreatic cancer is among the deadliest malignancies known to medicine. The five-year survival rate for pancreatic ductal adenocarcinoma (PDAC), which accounts for over 90 percent of all pancreatic cancers, sits at around 12 percent. Most patients are diagnosed at an advanced, inoperable stage, and the disease is notoriously resistant to standard chemotherapy.
Research into pancreatic cancer biology and new treatment strategies depends heavily on reliable in vitro models. PANC-1 and MiaPaCa-2 are the two most widely used pancreatic cancer cell lines in the world, appearing in thousands of published studies. This guide explains what each line is, how they compare, when to use each one, and which additional lines researchers reach for in specific contexts.
Why Pancreatic Cancer Is Difficult to Study
PDAC presents unique research challenges. Tumors are surrounded by a dense fibrotic stroma that limits drug delivery, fuels immune evasion, and contributes to resistance. Nearly all PDAC tumors carry KRAS mutations, making KRAS one of the most important but historically undruggable targets in oncology.
Primary pancreatic tumor cultures are technically difficult to establish and maintain. Established cell lines like PANC-1 and MiaPaCa-2, despite their limitations, remain the most practical and accessible starting point for pancreatic cancer research.
PANC-1
Origin and Background
PANC-1 was established in 1975 from the primary pancreatic ductal epithelial tumor of a 56 year old male patient. It is one of the oldest and most extensively characterized pancreatic cancer cell lines available, with a long publication history spanning basic biology, drug testing, and signaling pathway research.
Key Genetic Features
PANC-1 carries a KRAS G12D mutation, which constitutively activates RAS signaling and drives continuous proliferation. It also carries mutant TP53, homozygous deletion of CDKN2A (the p16 tumor suppressor), and is SMAD4 wild-type, which distinguishes it from the majority of clinical PDAC cases where SMAD4 loss is common.
PANC-1 cells show pleomorphic morphology and express vimentin but not E-cadherin, placing them toward the mesenchymal end of the epithelial-to-mesenchymal transition (EMT) spectrum. This mesenchymal phenotype is associated with increased invasive capacity and drug resistance.
Notably, PANC-1 also expresses neuroendocrine markers including chromogranin A and SSTR2 (somatostatin receptor 2), features that may be relevant for studies of neuroendocrine-targeted therapies in pancreatic cancer.
Biological Characteristics
PANC-1 cells grow as adherent monolayers with a doubling time of approximately 38 to 52 hours. They are moderately tumorigenic in immunodeficient mouse models and show invasive behavior in in vitro assays. They form three-dimensional spheroids under non-adherent conditions, which are used to model aspects of pancreatic tumor architecture.
PANC-1 cells exhibit higher stemness features compared to MiaPaCa-2, with greater expression of cancer stem cell markers. This makes them particularly useful for studies targeting the stem-like subpopulation within pancreatic tumors, which is thought to drive chemotherapy resistance and disease recurrence.
Research Applications
PANC-1 is used across a broad range of applications including KRAS pathway inhibition studies, EMT and invasion research, cancer stem cell biology, CRISPR-based gene editing experiments, and evaluation of SSTR2-targeted therapies. Its well-characterized genetic profile and long history in the literature make it a reliable reference line for comparative studies.
MiaPaCa-2
Origin and Background
MiaPaCa-2 was established in 1975 from a primary pancreatic tumor of a 65 year old male patient. Like PANC-1, it has been in continuous use for decades and has an extensive body of published data associated with it, making it easy for researchers to contextualize their own findings against existing literature.
Key Genetic Features
MiaPaCa-2 carries a KRAS G12C mutation, the same type of mutation that has attracted significant attention with the development of KRAS G12C-specific inhibitors like sotorasib. This makes MiaPaCa-2 particularly relevant for research into direct KRAS targeting, which has been one of the most pursued goals in pancreatic cancer drug discovery.
Like PANC-1, MiaPaCa-2 carries mutant TP53 and homozygous deletion of CDKN2A. It is SMAD4 wild-type. The cells express both epithelial markers (E-cadherin) and mesenchymal markers (vimentin), suggesting a hybrid EMT phenotype.
MiaPaCa-2 also expresses SSTR2, making it, like PANC-1, a potential model for somatostatin receptor-targeted approaches.
Biological Characteristics
MiaPaCa-2 cells grow faster than PANC-1, with a doubling time of approximately 24 to 40 hours. They are highly tumorigenic in immunodeficient mice: when equal numbers of MiaPaCa-2 and PANC-1 cells are injected intraperitoneally into SCID mice, MiaPaCa-2 tumors grow larger. This high in vivo tumorigenicity makes them a preferred choice for xenograft efficacy studies.
MiaPaCa-2 cells are resistant to high doses of gemcitabine, the backbone chemotherapy drug for pancreatic cancer treatment. This gemcitabine resistance makes them a practical model for studying resistance mechanisms and evaluating drugs that might overcome or bypass standard chemotherapy failure.
Research Applications
MiaPaCa-2 is frequently used for KRAS G12C inhibitor studies, gemcitabine resistance research, in vivo xenograft efficacy experiments, EMT and metastasis biology, and drug combination strategies. Its faster growth rate and high xenograft tumorigenicity make it the practical choice when large numbers of cells or reliable in vivo tumor formation is needed quickly.
PANC-1 vs MiaPaCa-2: Direct Comparison
KRAS Mutation: PANC-1 carries KRAS G12D. MiaPaCa-2 carries KRAS G12C, which is specifically targetable with approved inhibitors.
TP53: Both carry mutant TP53.
SMAD4: Both are SMAD4 wild-type, distinguishing them from the majority of clinical PDAC tumors.
EMT Phenotype: PANC-1 is more mesenchymal (E-cadherin negative). MiaPaCa-2 shows a hybrid epithelial/mesenchymal phenotype.
Doubling Time: PANC-1 is slower at 38 to 52 hours. MiaPaCa-2 is faster at 24 to 40 hours.
In Vivo Tumorigenicity: MiaPaCa-2 forms larger tumors more reliably than PANC-1 in mouse xenograft models.
Gemcitabine Resistance: MiaPaCa-2 shows high resistance. PANC-1 shows moderate resistance.
Stemness: PANC-1 shows higher cancer stem cell marker expression than MiaPaCa-2.
Additional Pancreatic Cancer Cell Lines
BxPC-3
BxPC-3 is one of the few commonly used pancreatic cancer cell lines that carries wild-type KRAS, which makes it a valuable control or contrast line when studying KRAS-specific biology. It carries mutant SMAD4, reflecting the loss of this tumor suppressor seen in approximately 55 percent of clinical PDAC cases. BxPC-3 cells are slower-growing and less invasive than PANC-1 or MiaPaCa-2, and they are more sensitive to gemcitabine, making them useful in drug sensitivity comparisons.
AsPC-1
AsPC-1 was derived from the ascitic fluid of a patient with metastatic pancreatic cancer and represents late-stage, disseminated disease. It carries KRAS G12D and SMAD4 loss, making it genetically closer to the typical clinical PDAC profile than PANC-1 or MiaPaCa-2. AsPC-1 is highly resistant to gemcitabine and is used in studies of advanced, treatment-refractory pancreatic cancer.
Capan-1 and Capan-2
Capan-1 was derived from a liver metastasis of a pancreatic adenocarcinoma patient and carries a BRCA2 mutation, making it relevant for studies of PARP inhibitor sensitivity in pancreatic cancer, an emerging area of clinical interest. Capan-2 was derived from a primary tumor and retains wild-type KRAS, providing another KRAS wild-type comparison model alongside BxPC-3.
SW1990
SW1990 was derived from a spleen metastasis of a pancreatic adenocarcinoma and carries KRAS G12D and SMAD4 loss. It is used in studies of invasion, metastasis, and drug resistance and is included in some comparative pancreatic cancer cell line panels.
How to Choose the Right Pancreatic Cancer Cell Line
For KRAS G12C Inhibitor Studies
MiaPaCa-2 is the standard choice. It is one of the few pancreatic cancer cell lines with a KRAS G12C mutation, making it the most clinically relevant model for this specific drug class.
For Cancer Stem Cell and EMT Research
PANC-1 is preferred. Its higher stemness marker expression and more mesenchymal phenotype make it better suited for studying the stem-like subpopulation and the invasion-promoting properties of EMT.
For In Vivo Xenograft Studies
MiaPaCa-2 is the practical choice due to its higher and more consistent tumorigenicity in immunodeficient mice. This matters greatly in drug discovery and screening workflows where in vivo efficacy confirmation is a required step before advancing a compound.
For KRAS Wild-Type Comparisons
BxPC-3 or Capan-2 are the appropriate choices when a KRAS wild-type background is needed as a contrast to KRAS-mutant lines.
For BRCA2-Related Research
Capan-1, with its BRCA2 mutation, is the standard model for studying homologous recombination deficiency and PARP inhibitor sensitivity in pancreatic cancer.
For A Broad Panel
Researchers evaluating new compounds across the spectrum of PDAC biology typically use a panel that includes PANC-1 or MiaPaCa-2 (KRAS mutant), BxPC-3 (KRAS wild-type), and AsPC-1 (SMAD4 loss, gemcitabine resistant). AstralCell provides authenticated pancreatic cancer cell lines including these major models with in-house quality control verification.
Culture Conditions
PANC-1
Grows in DMEM supplemented with 10 percent fetal bovine serum. Cells are passaged at 80 to 90 percent confluence. Standard incubation at 37 degrees Celsius with 5 percent CO2.
MiaPaCa-2
Grows in DMEM supplemented with 10 percent fetal bovine serum and 2.5 percent horse serum, an unusual requirement that is specific to this cell line. The horse serum supplementation is important and should not be omitted. Standard incubation conditions apply.
Authentication and Quality Control
Both PANC-1 and MiaPaCa-2 are well-established lines with documented STR profiles available through ATCC and DSMZ. Given the importance of KRAS mutation type in interpreting drug response data, using an incorrectly authenticated or contaminated culture could fundamentally alter experimental conclusions. Regular STR profiling authentication is strongly recommended. For more detail on why this matters and how the process works, see our guide on cell line authentication.
Frequently Asked Questions
What is PANC-1 used for?
PANC-1 is used for KRAS pathway research, EMT and invasion studies, cancer stem cell biology, CRISPR experiments, and evaluation of neuroendocrine-targeted therapies in pancreatic cancer.
What is MiaPaCa-2 used for?
MiaPaCa-2 is used for KRAS G12C inhibitor studies, gemcitabine resistance research, in vivo xenograft studies, and drug combination experiments in pancreatic cancer.
What is the KRAS mutation in PANC-1?
PANC-1 carries a KRAS G12D mutation. MiaPaCa-2 carries a KRAS G12C mutation. The difference matters because KRAS G12C is specifically targetable with approved inhibitors like sotorasib.
Is MiaPaCa-2 resistant to gemcitabine?
Yes. MiaPaCa-2 shows high resistance to gemcitabine, the standard pancreatic cancer chemotherapy drug. This makes it a useful model for studying resistance mechanisms and identifying strategies to overcome treatment failure.
Which pancreatic cancer cell line has wild-type KRAS?
BxPC-3 and Capan-2 are the most commonly used KRAS wild-type pancreatic cancer cell lines, often used as controls or contrast lines in studies of KRAS-specific biology.
What culture medium does MiaPaCa-2 require?
DMEM with 10 percent FBS and 2.5 percent horse serum. The horse serum is a specific requirement for MiaPaCa-2 and should not be substituted or omitted.
Do PANC-1 and MiaPaCa-2 need to be authenticated?
Yes. Both lines have well-documented STR profiles and should be authenticated before use, particularly given how much experimental interpretation depends on their specific KRAS mutation status.